Research ExplorerPublicationsTreatment of drug-susceptible and drug-resistant tuberculosi...

Treatment of drug-susceptible and drug-resistant tuberculosis

Standard

Treatment of drug-susceptible and drug-resistant tuberculosis. / Lange, Christoph; Brehm, Thomas Theo; Chesov, Dumitru; Kherabi, Yousra; Guglielmetti, Lorenzo.

The Challenge of Tuberculosis in the 21st Century. ed. / Alberto L. García-Basteiro; Füsun Öner Eyüboglu; Molebogeng X. Rangaka. 3. ed. Sheffield : European Respiratory Society, 2023. p. 117-138 (ERS Monograph).

Research output: SCORING: Contribution to book/anthology › SCORING: Contribution to collected editions/anthologies › Research

Harvard

Lange, C, Brehm, TT, Chesov, D, Kherabi, Y & Guglielmetti, L 2023, Treatment of drug-susceptible and drug-resistant tuberculosis. in AL García-Basteiro, FÖ Eyüboglu & MX Rangaka (eds), The Challenge of Tuberculosis in the 21st Century. 3 edn, ERS Monograph, European Respiratory Society, Sheffield, pp. 117-138. https://doi.org/10.1183/2312508X.10024622

APA

Lange, C., Brehm, T. T., Chesov, D., Kherabi, Y., & Guglielmetti, L. (2023). Treatment of drug-susceptible and drug-resistant tuberculosis. In A. L. García-Basteiro, F. Ö. Eyüboglu, & M. X. Rangaka (Eds.), The Challenge of Tuberculosis in the 21st Century (3 ed., pp. 117-138). (ERS Monograph). European Respiratory Society. https://doi.org/10.1183/2312508X.10024622

Vancouver

Lange C, Brehm TT, Chesov D, Kherabi Y, Guglielmetti L. Treatment of drug-susceptible and drug-resistant tuberculosis. In García-Basteiro AL, Eyüboglu FÖ, Rangaka MX, editors, The Challenge of Tuberculosis in the 21st Century. 3 ed. Sheffield: European Respiratory Society. 2023. p. 117-138. (ERS Monograph). https://doi.org/10.1183/2312508X.10024622

Bibtex

@inbook{c803906063774c65aa067d0dab41154a,
title = "Treatment of drug-susceptible and drug-resistant tuberculosis",
abstract = "Recent advances have enabled the use of shorter TB treatment regimens. Key changes in the management of TB are: 1-month preventive treatment with rifapentine and isoniazid 4-month treatment for paucibacillary TB in children 4-month treatment for PTB in adults based on rifapentine and 6-month treatment for MDR/RR-TB with bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM). However, the history of TB drug resistance, and limited capacity worldwide for DST, are cause for caution.",
author = "Christoph Lange and Brehm, {Thomas Theo} and Dumitru Chesov and Yousra Kherabi and Lorenzo Guglielmetti",
year = "2023",
month = sep,
day = "1",
doi = "10.1183/2312508X.10024622",
language = "Deutsch",
isbn = "978-1-84984-169-6",
series = "ERS Monograph",
publisher = "European Respiratory Society",
pages = "117--138",
editor = "Garc{\'i}a-Basteiro, {Alberto L.} and Ey{\"u}boglu, {F{\"u}sun {\"O}ner} and Rangaka, {Molebogeng X.}",
booktitle = "The Challenge of Tuberculosis in the 21st Century",
address = "Schweiz",
edition = "3",

}

RIS

TY - CHAP

T1 - Treatment of drug-susceptible and drug-resistant tuberculosis

AU - Lange, Christoph

AU - Brehm, Thomas Theo

AU - Chesov, Dumitru

AU - Kherabi, Yousra

AU - Guglielmetti, Lorenzo

PY - 2023/9/1

Y1 - 2023/9/1

N2 - Recent advances have enabled the use of shorter TB treatment regimens. Key changes in the management of TB are: 1-month preventive treatment with rifapentine and isoniazid 4-month treatment for paucibacillary TB in children 4-month treatment for PTB in adults based on rifapentine and 6-month treatment for MDR/RR-TB with bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM). However, the history of TB drug resistance, and limited capacity worldwide for DST, are cause for caution.

AB - Recent advances have enabled the use of shorter TB treatment regimens. Key changes in the management of TB are: 1-month preventive treatment with rifapentine and isoniazid 4-month treatment for paucibacillary TB in children 4-month treatment for PTB in adults based on rifapentine and 6-month treatment for MDR/RR-TB with bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM). However, the history of TB drug resistance, and limited capacity worldwide for DST, are cause for caution.

U2 - 10.1183/2312508X.10024622

DO - 10.1183/2312508X.10024622

M3 - SCORING: Beitrag in Sammelwerk

SN - 978-1-84984-169-6

T3 - ERS Monograph

SP - 117

EP - 138

BT - The Challenge of Tuberculosis in the 21st Century

A2 - García-Basteiro, Alberto L.

A2 - Eyüboglu, Füsun Öner

A2 - Rangaka, Molebogeng X.

PB - European Respiratory Society

CY - Sheffield

ER -